Forbes speaks about our preprint on vaccine effectivenesshttps://www.forbes.com/sites/nicholasreimann/2021/07/20/johnson--johnson-vaccine-far-less-effective-against-delta-variant-study-suggests/?sh=5ce80b824299
Medpage Today covered our work on the Lamda Varianthttps://www.medpagetoday.com/special-reports/exclusives/93458
